Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa in mCRPC (SP001)
NCT02105675Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Feb 2012
- Primary completion
- Mar 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of stapuldencel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOTIO Biotech. Started Feb 2012; status: completed.
02
Drugs
stapuldencel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02105675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105675.